Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
GSK exclusive license agreement for HS-20089 with Hansoh Pharma
We advised GSK on the transaction
GSK collaboration extension and new data licensing agreement with 23andMe
We advised GSK on the transaction
IDEAYA Biosciences $143.8 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Aligos Therapeutics $92 million private placement
The PIPE included common stock and warrants
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction
Roivant Sciences registered direct offering and investment in Immunovant
We advised Roivant on the transactions
Inventiva $58 million at-the-market offering
The American depositary shares are listed on Nasdaq
HilleVax $115 million follow-on offering
The shares are listed on the Nasdaq Global Select Market